高级检索
    徐海鹏, 林根, 黄婕. 帕博丽珠单抗联合依托泊苷和铂类一线治疗小细胞肺癌:KEYNOTE-604研究[J]. 循证医学, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
    引用本文: 徐海鹏, 林根, 黄婕. 帕博丽珠单抗联合依托泊苷和铂类一线治疗小细胞肺癌:KEYNOTE-604研究[J]. 循证医学, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
    shu
    XU Hai-peng, LIN Gen, HUANG Jie. Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
    Citation: XU Hai-peng, LIN Gen, HUANG Jie. Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study[J]. Journal of Evidence-Based Medicine, 2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
    shu

    帕博丽珠单抗联合依托泊苷和铂类一线治疗小细胞肺癌:KEYNOTE-604研究

    Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study

      摘要
      • HTML全文
      • 参考文献(5)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回